di Cola, F.S.; Bolchini, M.; Caratozzolo, S.; Ceccardi, G.; Cortinovis, M.; Liberini, P.; Rao, R.; Padovani, A.
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine. Neurol. Int. 2023, 15, 273-284.
https://doi.org/10.3390/neurolint15010017
AMA Style
di Cola FS, Bolchini M, Caratozzolo S, Ceccardi G, Cortinovis M, Liberini P, Rao R, Padovani A.
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine. Neurology International. 2023; 15(1):273-284.
https://doi.org/10.3390/neurolint15010017
Chicago/Turabian Style
di Cola, Francesca Schiano, Marco Bolchini, Salvatore Caratozzolo, Giulia Ceccardi, Matteo Cortinovis, Paolo Liberini, Renata Rao, and Alessandro Padovani.
2023. "Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine" Neurology International 15, no. 1: 273-284.
https://doi.org/10.3390/neurolint15010017
APA Style
di Cola, F. S., Bolchini, M., Caratozzolo, S., Ceccardi, G., Cortinovis, M., Liberini, P., Rao, R., & Padovani, A.
(2023). Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine. Neurology International, 15(1), 273-284.
https://doi.org/10.3390/neurolint15010017
